Agilent Technologies, Inc. (NYSE:A) Given Consensus Rating of "Moderate Buy" by Analysts

FierceBiotechADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes

Clinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune Disease

CellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvation

CellReplaying germinal center evolution on a quantified affinity landscape

CellXenophagocytosis blockade enhances interspecies chimerism

FierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy

Endpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetes

Endpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year

Endpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and more

FierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs

Brady CorporationLabel Maker Market Forecast Points Higher Toward 2035, Driven by Commercial Micro-Enterprise Demand - IndexBox